iBio announces new preclinical data for Activin E antibody

iBio (IBIO) announced new promising preclinical data for its first-in-class Activin E antibody unveiled in January. Data from the recently completed 4-week study in diet-induced obese mice show a 26% reduction in fat mass following treatment with the Activin E antibody, with muscle mass fully preserved. These findings highlight a significant fat loss can be achieved without the double-digit weight reductions typically required by other obesity drugs. The study also analyzed specific fat depots in obese mice and found a significant 31% reduction in subcutaneous fat. More notably, reductions of 34% and 37% were observed in the epididymal and retroperitoneal fat depots, respectively-both of which are forms of visceral fat closely linked to increased risk of cardiometabolic disease. When combined with a GLP-1 receptor agonist, the Activin E antibody produced additive effects, reducing total fat mass by 77%. Subcutaneous fat loss increased to 74%, while visceral fat depots-epididymal and retroperitoneal-were reduced by 69% and 81%, respectively.